Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

First International Summit on Interventional Pharmacoeconomics

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Dec

Today In Oncology

Javid J. Moslehi, MD, on Cardiovascular and Thrombotic Considerations of Kinase Inhibitors: The Case of BTK Inhibitors

Related Videos

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers

FDA Grants Traditional Approval to Pirtobrutinib for CLL/SLL

Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening

AYA Cancers Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease

Survey Finds Global Embrace of Integrative Cancer Care